Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with favorable safety data.

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

Experts view BridgeBio’s acoramidis—which has an FDA action date of Nov. 29—as either similar to or incrementally better than ...

Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new study from Karolinska ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

(TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug ...

Valuable data can successfully be collected with the noninvasive wearable, which is worn on the sternum, report investigators ...

StudyFinds' Dr. Faith Coleman reveals her tips for maintaining good sexual function, even as men reach their senior years.

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

German drugs-to-crops giant Bayer will have an exclusive license to develop and commercialize aficamten in Japan. Cytokinetics has filed for U.S. Food & Drug Administration approval of aficamten in ...